Prognostic factors and adjuvant therapy in uterine carcinosarcoma

T. I. Wu, K. H. Hsu, H. J. Huang, S. Hsueh, H. H. Chou, C. S. Tsai, K. C. Ho, A. Chao, T. C. Chang, C. H. Lai

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Purpose of investigation: The objective of this retrospective study was to investigate prognostic variables and impact of adjuvant therapy in uterine carcinosarcoma. Methods: The clinical information and pathological confirmation were reviewed for cases with uterine carcinosarcoma from 1984 to 2005. A total of 45 patients were eligible for analysis. Results: The median follow-up for survivors was 84 months. Five-year overall survival and progression-free survival (PFS) rates were 36.5% and 33.8%, respectively for Stage I-IV. Distant site metastasis with/ without pelvic failure occurred in 83.3% of those with recurrence/ progression. By multivariate analysis, older age (p = 0.001) and more than half of myometrial invasion (p = 0.002) were significant predictors of death, while only myometrial invasion (p = 0.022) was significantly associated with PFS. Stratified analyses demonstrated a monotonic trend of chemotherapy or chemoradiation to decrease death. Conclusions: Our results suggested that age and depth of myometrial invasion were significant prognostic factors, and chemotherapy or chemoradiation seemed to be beneficial for uterine carcinosarcoma.

Original languageEnglish
Pages (from-to)483-488
Number of pages6
JournalEuropean Journal of Gynaecological Oncology
Volume29
Issue number5
Publication statusPublished - 2008
Externally publishedYes

Fingerprint

Carcinosarcoma
Disease-Free Survival
Drug Therapy
Survivors
Therapeutics
Multivariate Analysis
Survival Rate
Retrospective Studies
Neoplasm Metastasis
Recurrence
Survival

Keywords

  • Chemoradiation
  • Chemotherapy
  • Malignant mixed müllerian tumor
  • Prognostic factor
  • Uterine carcinosarcoma

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology

Cite this

Wu, T. I., Hsu, K. H., Huang, H. J., Hsueh, S., Chou, H. H., Tsai, C. S., ... Lai, C. H. (2008). Prognostic factors and adjuvant therapy in uterine carcinosarcoma. European Journal of Gynaecological Oncology, 29(5), 483-488.

Prognostic factors and adjuvant therapy in uterine carcinosarcoma. / Wu, T. I.; Hsu, K. H.; Huang, H. J.; Hsueh, S.; Chou, H. H.; Tsai, C. S.; Ho, K. C.; Chao, A.; Chang, T. C.; Lai, C. H.

In: European Journal of Gynaecological Oncology, Vol. 29, No. 5, 2008, p. 483-488.

Research output: Contribution to journalArticle

Wu, TI, Hsu, KH, Huang, HJ, Hsueh, S, Chou, HH, Tsai, CS, Ho, KC, Chao, A, Chang, TC & Lai, CH 2008, 'Prognostic factors and adjuvant therapy in uterine carcinosarcoma', European Journal of Gynaecological Oncology, vol. 29, no. 5, pp. 483-488.
Wu TI, Hsu KH, Huang HJ, Hsueh S, Chou HH, Tsai CS et al. Prognostic factors and adjuvant therapy in uterine carcinosarcoma. European Journal of Gynaecological Oncology. 2008;29(5):483-488.
Wu, T. I. ; Hsu, K. H. ; Huang, H. J. ; Hsueh, S. ; Chou, H. H. ; Tsai, C. S. ; Ho, K. C. ; Chao, A. ; Chang, T. C. ; Lai, C. H. / Prognostic factors and adjuvant therapy in uterine carcinosarcoma. In: European Journal of Gynaecological Oncology. 2008 ; Vol. 29, No. 5. pp. 483-488.
@article{6fe1e892dd1348c299103a8478cd7dd0,
title = "Prognostic factors and adjuvant therapy in uterine carcinosarcoma",
abstract = "Purpose of investigation: The objective of this retrospective study was to investigate prognostic variables and impact of adjuvant therapy in uterine carcinosarcoma. Methods: The clinical information and pathological confirmation were reviewed for cases with uterine carcinosarcoma from 1984 to 2005. A total of 45 patients were eligible for analysis. Results: The median follow-up for survivors was 84 months. Five-year overall survival and progression-free survival (PFS) rates were 36.5{\%} and 33.8{\%}, respectively for Stage I-IV. Distant site metastasis with/ without pelvic failure occurred in 83.3{\%} of those with recurrence/ progression. By multivariate analysis, older age (p = 0.001) and more than half of myometrial invasion (p = 0.002) were significant predictors of death, while only myometrial invasion (p = 0.022) was significantly associated with PFS. Stratified analyses demonstrated a monotonic trend of chemotherapy or chemoradiation to decrease death. Conclusions: Our results suggested that age and depth of myometrial invasion were significant prognostic factors, and chemotherapy or chemoradiation seemed to be beneficial for uterine carcinosarcoma.",
keywords = "Chemoradiation, Chemotherapy, Malignant mixed m{\"u}llerian tumor, Prognostic factor, Uterine carcinosarcoma",
author = "Wu, {T. I.} and Hsu, {K. H.} and Huang, {H. J.} and S. Hsueh and Chou, {H. H.} and Tsai, {C. S.} and Ho, {K. C.} and A. Chao and Chang, {T. C.} and Lai, {C. H.}",
year = "2008",
language = "English",
volume = "29",
pages = "483--488",
journal = "European Journal of Gynaecological Oncology",
issn = "0392-2936",
publisher = "S.O.G. CANADA Inc.",
number = "5",

}

TY - JOUR

T1 - Prognostic factors and adjuvant therapy in uterine carcinosarcoma

AU - Wu, T. I.

AU - Hsu, K. H.

AU - Huang, H. J.

AU - Hsueh, S.

AU - Chou, H. H.

AU - Tsai, C. S.

AU - Ho, K. C.

AU - Chao, A.

AU - Chang, T. C.

AU - Lai, C. H.

PY - 2008

Y1 - 2008

N2 - Purpose of investigation: The objective of this retrospective study was to investigate prognostic variables and impact of adjuvant therapy in uterine carcinosarcoma. Methods: The clinical information and pathological confirmation were reviewed for cases with uterine carcinosarcoma from 1984 to 2005. A total of 45 patients were eligible for analysis. Results: The median follow-up for survivors was 84 months. Five-year overall survival and progression-free survival (PFS) rates were 36.5% and 33.8%, respectively for Stage I-IV. Distant site metastasis with/ without pelvic failure occurred in 83.3% of those with recurrence/ progression. By multivariate analysis, older age (p = 0.001) and more than half of myometrial invasion (p = 0.002) were significant predictors of death, while only myometrial invasion (p = 0.022) was significantly associated with PFS. Stratified analyses demonstrated a monotonic trend of chemotherapy or chemoradiation to decrease death. Conclusions: Our results suggested that age and depth of myometrial invasion were significant prognostic factors, and chemotherapy or chemoradiation seemed to be beneficial for uterine carcinosarcoma.

AB - Purpose of investigation: The objective of this retrospective study was to investigate prognostic variables and impact of adjuvant therapy in uterine carcinosarcoma. Methods: The clinical information and pathological confirmation were reviewed for cases with uterine carcinosarcoma from 1984 to 2005. A total of 45 patients were eligible for analysis. Results: The median follow-up for survivors was 84 months. Five-year overall survival and progression-free survival (PFS) rates were 36.5% and 33.8%, respectively for Stage I-IV. Distant site metastasis with/ without pelvic failure occurred in 83.3% of those with recurrence/ progression. By multivariate analysis, older age (p = 0.001) and more than half of myometrial invasion (p = 0.002) were significant predictors of death, while only myometrial invasion (p = 0.022) was significantly associated with PFS. Stratified analyses demonstrated a monotonic trend of chemotherapy or chemoradiation to decrease death. Conclusions: Our results suggested that age and depth of myometrial invasion were significant prognostic factors, and chemotherapy or chemoradiation seemed to be beneficial for uterine carcinosarcoma.

KW - Chemoradiation

KW - Chemotherapy

KW - Malignant mixed müllerian tumor

KW - Prognostic factor

KW - Uterine carcinosarcoma

UR - http://www.scopus.com/inward/record.url?scp=54949140459&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54949140459&partnerID=8YFLogxK

M3 - Article

C2 - 19051818

AN - SCOPUS:54949140459

VL - 29

SP - 483

EP - 488

JO - European Journal of Gynaecological Oncology

JF - European Journal of Gynaecological Oncology

SN - 0392-2936

IS - 5

ER -